Paxista Nirmatrelvir 150mg Tablets Description :
Nirmatrelvir is an oral protease inhibitor that is dynamic against MPRO, a viral protease that assumes a fundamental part in viral replication by cutting the 2 viral polyproteins.1 It has exhibited antiviral movement against all Covids that are known to taint humans.2 Nirmatrelvir is bundled with ritonavir (as Paxlovid), a solid cytochrome P450 (CYP) 3A4 inhibitor and pharmacokinetic helping specialist that has been utilized to support HIV protease inhibitors. Coadministration of ritonavir is expected to increment nirmatrelvir focuses to the objective remedial reach. The Food and Medication Organization (FDA) gave a Crisis Use Approval (EUA) for ritonavir-supported nirmatrelvir on December 22, 2021, for the treatment of Coronavirus.
Brand Name:
Product Specification
Packaging Size | Combipack |
Composition | Nirmatrelvir ritonavir |
Treatment | Covid |
Prescription/Non prescription | Prescription |
Form | Tablet |
Shelf life | Year |
Drug Name | Paxista |
Pack Type | 3×10 |
Packing Type | 3×10 |
No | N |
Reviews
There are no reviews yet.